NOW
6Fr
compatible

GREATER
VERSATILITY

GORE® VIABAHN® VBX
Balloon Expandable Endoprosthesis

TRUSTED PERFORMANCE. UNMATCHED VERSATILITY.*

* Across indication inclusivity and configuration breadth/capability of balloon expandable covered stents.

Together, improving life

Trusted procedural and clinical performance

The Gore VBX FLEX Clinical Study is a prospective, multicenter, single-arm study of 134 patients with complex aortoiliac occlusive disease (32.1% TASC II C & D, 42.5% kissing stent).

In the study, 234 devices were delivered; 50% bilateral treatment, 18% contralateral deliveries and predilitation was not required.

100%

restoration of lumen diameter[1]



Before After

Procedural outcomes based on usage of legacy GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis. (BXA catalogue numbers.)

< 30% residual stenosis due to high radial strength, even in highly calcified and non-compliant lesions[1]

100%

delivery to target lesion with no device dislodgement[1]

100%

stent retention[1]

100%

deployment at the target site[1]

Trusted patency and patient benefit

1-year outcomes

94.5%
primary patency[2]

96.1% primary patency in TASC C & D lesions at 1 year*

99.5% secondary patency[2]

3-year outcomes

91.2% freedom from target lesion revascularization (fTLR)[2]

+.17 improvement in mean resting ankle-brachial index (ABI) ($P < .001$, .93 mean ABI)[2]

92% of patients improved ≥ 1 Rutherford category vs. baseline[2]

* Data on file 2020; W. L. Gore & Associates, Inc; Flagstaff, AZ.

Trusted clinical results

VBX Stent Graft durability through 5 years assessed in a physician-initiated study that enrolled 59 patients from 3 participating centers representative of the VBX FLEX Study cohort.

Physician-initiated **5-year** follow-up of patients from 3 centers participating in the VBX FLEX Study

5-year outcomes

89.5%
primary patency per lesion[3]

96.1%
primary assisted patency per lesion[3]

89.1%
fTLR per subject[3]



Kaplan-Meier graph of primary patency with number of lesions at risk

Additional patient benefits vs. baseline

Follow-up of patients treated with the **VBX Stent Graft**

5-year outcomes

+.15	improvement in mean resting ABI (from .82 to .95) [$P < .001$][3]
3x	improvement in median walking impairment questionnaire (WIQ) measures[3]
100%	of patients improved ≥ 1 Rutherford category vs. baseline[3]

Procedural economic value

The VBX Stent Graft delivers an estimated savings of $5,147/case over 3 years.*,[4]

Fewer devices
Long (79 mm) available lengths may reduce the total number of devices needed[4]

Fewer reinterventions
Relative to competitive devices as demonstrated in 3-year outcomes data[2,5,6]

Fewer dislodgements
Reliable delivery with no device dislodgements[1]

Fewer errors
Accurate placement helps avoid need for additional stent grafts[1]

* All costs adjusted for inflation to 2023 USD via U.S. Bureau of Labor Statistics (https://www.bls.gov/data/inflation_calculator.htm).

† Across indication inclusivity and configuration breadth/capability of balloon expandable covered stents.

‡ Technical limit of the device as determined by in-vitro testing for the indicated use; device expansion beyond 13 mm was not studied as part of the VBX FLEX Clinical Study and is outside of the approved indication — see *Instructions for Use*.

Unmatched versatility†

Broadest offering of diameters and lengths[7–9]

- The longest balloon expandable (BX) stent graft
- The biggest max post-dilated stent diameter BX stent graft‡
- The most 6 Fr compatible configurations



The only BX stent graft with stainless steel independent rings[7–9]

- Enhances flexibility and conformability
- Minimizes foreshortening
- Provides high radial strength



The only BX stent graft with a semi-compliant covered balloon[7–9]

- Enables diameter customization
- Improves device retention on the catheter while tracking in tortuous anatomy and tight angles

Proven leader in stent graft technology

- Twenty years of peripheral stent graft clinical experience
- Leverages the stent graft technology of the GORE® VIABAHN® Endoprosthesis
- Featuring Gore's CBAS® Heparin Surface, the proven heparin bonding technology for lasting thromboresistance[10]



References

1. Bismuth J, Gray BH, Holden A, Metzger C, Panneton J; VBX FLEX Study Investigators. Pivotal study of a next-generation balloon-expandable stent-graft for treatment of iliac occlusive disease. *Journal of Endovascular Therapy* 2017;24(5):629-637. http://journals.sagepub.com/doi/full/10.1177/1526602817720463
2. Panneton JM, Bismuth J, Gray BH, Holden A. Three-year follow-up of patients with iliac occlusive disease treated with the Viabahn Balloon-Expandable Endoprosthesis. *Journal of Endovascular Therapy* 2020;27(5):728-736. https://journals.sagepub.com/doi/10.1177/1526602820920569
3. Holden A, Takele E, Hill A, *et al*. Long-term follow-up of subjects with iliac occlusive disease treated with the Viabahn VBX Balloon-Expandable Endoprosthesis. *Journal of Endovascular Therapy*. In press.
4. W. L. Gore & Associates, Inc. *GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX Stent Graft)*. Clinical evaluation in aortoiliac occlusive disease. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2024. [Cost calculator]. 24PR1034-EN01.
5. Laird JR, Loja M, Zeller T, *et al*. iCAST balloon-expandable covered stent for iliac artery lesions: 3-year results from the iCARUS multicenter study. *Journal of Vascular & Interventional Radiology* 2019;30(6):822-829.e4.
6. Laird JR. The BOLSTER Study with LIFESTREAM covered stent in iliac lesions: 3-year outcomes. Presented at the Leipzig Interventional Course (LINC) 2019; January 22-25, 2019; Leipzig, Germany.
7. GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis [Instructions for Use]. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2023. MD169334.
8. LIFESTREAM® Balloon Expandable Vascular Covered Stent [Instructions for Use]. Tempe, AZ: Bard Peripheral Vascular, Inc; 2019. BAW1345700 Rev. 5 06/19.
9. iCast covered stent system [Instructions for Use]. Merrimack, NH: Atrium Medical Corporation; 2023. AW009603-EN Rev 11.
10. CBAS Heparin Surface. W. L. Gore & Associates website. Accessed July 8, 2024. https://www.goremedical.com/cbas/references

Consult Instructions for Use
eifu.goremedical.com

INDICATIONS FOR USE IN THE U.S.: The GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis is indicated for the treatment of de novo or restenotic lesions found in iliac arteries with reference vessel diameters ranging from 5 mm–13 mm and lesion lengths up to 110 mm, including lesions at the aortic bifurcation. The GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis is also indicated for use with thoracoabdominal and pararenal branched devices indicated with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis as a branch component.* **CONTRAINDICATIONS:** Do not use the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis in patients with known hypersensitivity to heparin, including those patients who have had a previous incident of Heparin-Induced Thrombocytopenia (HIT) type II. Refer to *Instructions for Use* at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. ℞ Only

* Not applicable to Reduced Profile GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis. (BXB catalogue numbers.)

Products listed may not be available in all markets.

W. L. Gore & Associates, Inc.
goremedical.com

Asia Pacific +65 6733 2882 **Australia/New Zealand** 1800 680 424 **Europe** 00800 6334 4673
United States Flagstaff, AZ 86004 800 437 8181 928 779 2771